Home LiteratureArticle Details
PMID: 34113576 Published · epublish English Journal Article

A Pan-Cancer Analysis of the Oncogenic Role of Twinfilin Actin Binding Protein 1 in Human Tumors.

Frontiers in oncology ·Vol. 11 ·2021-00-00 ·Pages 692136

Huo G, Wang Y, Chen J, Song Y, Zhang C, Guo H, Zuo R, Zhu F, Cui J, Chen W, Chen W, Chen P

Abstract

Understanding common and unique mechanisms driving oncogenic processes in human tumors is indispensable to develop efficient therapies. Recent studies have proposed Twinfilin Actin Binding Protein 1 (TWF1) as a putative driver gene in lung cancer, pancreatic cancer and breast cancer, however a systematic pan-cancer analysis has not been carried out. Here, we set out to explore the role of TWF1 in 33 tumor types using TCGA (The Cancer Genome Atlas), GEO (Gene Expression Omnibus) dataset, Human Protein Atlas (HPA), and several bioinformatic tools. As part of our analysis, we have assessed TWF1 expression across tumors. We found that over-expression of TWF1 generally predicted poor OS for patients with tumors with high TWF1 expression, such as mesothelioma, lung adenocarcinoma, cervical cancer and pancreatic adenocarcinoma. We also assessed the mutation burden of TWF1 in cancer and the TWF1-associated survival of cancer patients, compared the phosphorylation of TWF1 between normal and primary tumor tissues and explored putative functional mechanisms in TWF1-mediated oncogenesis. Our pan-cancer analysis provides a comprehensive overview of the oncogenic roles of TWF1 in multiple human cancers.

Keywords
TWF1 cancer phosphorylation prognosis survival
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Huo Gengwei
Department of Thoracic Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China. | Department of Oncology, Jining No.1 People's Hospital, Jining, China.
Wang Yali
Department of Thoracic Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Chen Jinliang
Department of Thoracic Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Song Ying
Department of Pharmacy, Jining No.1 People's Hospital, Jining, China.
Zhang Cuicui
Department of Thoracic Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Guo Hua
Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Zuo Ran
Department of Thoracic Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Zhu Fuyi
Department of Thoracic Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Cui Jinfang
Department of Thoracic Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Chen Weidong
Department of Oncology, Jining No.1 People's Hospital, Jining, China.
Chen Wenming
Department of Oncology, Jining No.1 People's Hospital, Jining, China.
Chen Peng
Department of Thoracic Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References (27)
27 references, click to expand
  1. Elevated expression of Twinfilin-1 is correlated with inferior prognosis of lung adenocarcinoma.
    Life Sci. 2018 Dec 15;215:159-169 PMID: 30391462
  2. In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression.
    Nat Genet. 2009 Oct;41(10):1133-7 PMID: 19783987
  3. SnapShot: TCGA-Analyzed Tumors.
    Cell. 2018 Apr 5;173(2):530 PMID: 29625059
  4. MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion.
    Breast Cancer Res Treat. 2013 Jan;137(2):373-82 PMID: 23224145
  5. MCTS1 Directly Binds to TWF1 and Synergistically Modulate Cyclin D1 and C-Myc Translation in Luminal A/B Breast Cancer Cells.
    Onco Targets Ther. 2020 Jun 10;13:5353-5361 PMID: 32606753
  6. MicroRNA-30c inhibits pancreatic cancer cell proliferation by targeting twinfilin 1 and indicates a poor prognosis.
    World J Gastroenterol. 2019 Nov 14;25(42):6311-6321 PMID: 31754292
  7. Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications.
    Cells. 2021 Jan 23;10(2): PMID: 33498711
  8. High-speed depolymerization at actin filament ends jointly catalysed by Twinfilin and Srv2/CAP.
    Nat Cell Biol. 2015 Nov;17(11):1504-11 PMID: 26458246
  9. Twinfilin is an actin-filament-severing protein and promotes rapid turnover of actin structures in vivo.
    J Cell Sci. 2006 Apr 15;119(Pt 8):1547-57 PMID: 16569665
  10. Twinfilin 1 enhances milk bio-synthesis and proliferation of bovine mammary epithelial cells via the mTOR signaling pathway.
    Biochem Biophys Res Commun. 2017 Oct 21;492(3):289-294 PMID: 28864421
  11. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11.
    Nat Commun. 2013;4:1393 PMID: 23340433
  12. A pan-cancer analysis of the oncogenic role of staphylococcal nuclease domain-containing protein 1 (SND1) in human tumors.
    Genomics. 2020 Nov;112(6):3958-3967 PMID: 32645525
  13. Twinfilin, a molecular mailman for actin monomers.
    J Cell Sci. 2002 Mar 1;115(Pt 5):881-6 PMID: 11870207
  14. Regulation of the cortical actin cytoskeleton in budding yeast by twinfilin, a ubiquitous actin monomer-sequestering protein.
    J Cell Biol. 1998 Aug 10;142(3):723-33 PMID: 9700161
  15. The ADF homology (ADF-H) domain: a highly exploited actin-binding module.
    Mol Biol Cell. 1998 Aug;9(8):1951-9 PMID: 9693358
  16. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis.
    Nucleic Acids Res. 2019 Jul 2;47(W1):W556-W560 PMID: 31114875
  17. Long non-coding SBF2-AS1 acting as a competing endogenous RNA to sponge microRNA-142-3p to participate in gemcitabine resistance in pancreatic cancer via upregulating TWF1.
    Aging (Albany NY). 2019 Nov 4;11(20):8860-8878 PMID: 31619579
  18. The Gene Expression Omnibus Database.
    Methods Mol Biol. 2016;1418:93-110 PMID: 27008011
  19. Structural basis and evolutionary origin of actin filament capping by twinfilin.
    Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3113-8 PMID: 17360616
  20. Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer.
    Cell Mol Immunol. 2019 Jan;16(1):6-18 PMID: 29628498
  21. Tumor suppressor miR-1 inhibits tumor growth and metastasis by simultaneously targeting multiple genes.
    Oncotarget. 2017 Jun 27;8(26):42043-42060 PMID: 28159933
  22. Increased Tumor Immune Microenvironment CD3+ and CD20+ Lymphocytes Predict a Better Prognosis in Oral Tongue Squamous Cell Carcinoma.
    Front Cell Dev Biol. 2021 Feb 18;8:622161 PMID: 33718347
  23. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge.
    Contemp Oncol (Pozn). 2015;19(1A):A68-77 PMID: 25691825
  24. Actin-depolymerizing factor homology domain: a conserved fold performing diverse roles in cytoskeletal dynamics.
    Cytoskeleton (Hoboken). 2011 Sep;68(9):471-90 PMID: 21850706
  25. miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway.
    Clin Cancer Res. 2017 Feb 15;23(4):1091-1103 PMID: 27435395
  26. Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers.
    Nat Commun. 2019 Dec 12;10(1):5679 PMID: 31831737
  27. Mammalian twinfilin sequesters ADP-G-actin and caps filament barbed ends: implications in motility.
    EMBO J. 2006 Mar 22;25(6):1184-95 PMID: 16511569
Full Text / Full Text
PMC full text available locally, click to read

Loading full text...

Article Info
Journal
Frontiers in oncology
Abbr.
Front Oncol
ISSN
2234-943X
Published
2021-00-00
Epub
2021-00-25
Pages
692136
Language
English
Region
Switzerland
NLM ID
101568867
PMCID
PMC8185641
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com